The scientific programme included
keynote speeches on 20th June
by three Principal Investigators
from ICGEB New Delhi, Dr Pawan
Malhotra, Dr Neel Sarovan Bhavesh
and Dr Dhiraj Kumar; further
cementing the strong scientific
and cultural ties across the ICGEB
international community.
The social programme included
the 5th edition of the ICGEB Fun
Run, a non-competitive, open track
race that takes place on the Karst
surrounding the Science Park.
This year, a record number of 150
participants took part in the event.
ZYDUS CADILA BEGINS PHASE-2
TRIAL OF DRUG TO CURE
ANAEMIA IN KIDEY PATIENTS
Anaemia commonly arises in
kidney disease patients, because
the kidneys no
longer produce
sufficient
amounts of
erythropoietin,
a hormone
which
stimulates
red blood cell production. It is
considered to be a major medical
problem in both developed as well
as developing nations.
In a new development in
this direction, the Cadila
Pharmaceuticals, also known
as Zydus Cadila has announced
commencement of a Phase-II
trial investigating Zyani1, an
oral hypoxia-inducible factor
prolyl hydroxylase inhibitor
(HIF-PHI), as a treatment for
anaemia associated with chronic
kidney disease (CKD).
The occasion
was marked
with a convivial
celebration
during ICGEB’s
22nd Annual
Symposium on 20 and 21 June
2017; two intense days during
which young, dedicated researchers
present their projects and results to
colleagues and Group Leaders.
In a statement issued in
Ahmedabad by Mr Pankaj Patel,
Chairman and Managing Director,
Zydus Cadila mentioned, “Zyani1
is an oral small molecule designed
to increase natural production of
haemoglobin and RBCs in anaemic
patients. It has been shown to
improve iron mobilisation and has
the potential to reduce or eliminate
the need for iron supplementation.”
BIOVOICENEWS.COM
61